# Asish Xavier > Asish Xavier is a Series C investor at Johnson & Johnson Development Corporation backing Biotechnology. See 14 investments, check sizes, portfolio. Updated… - Type: Angel Investor - Fund: [Johnson & Johnson Development Corporation](https://shizune.co/investors/profile/johnson-johnson-development-corporation) - Location: Menlo Park, United States - Total investments: 14 - Last investment: Jun 2026 - Lead investor: 21% - Last updated: Aug 2026 - LinkedIn: https://www.linkedin.com/in/asish-xavier-b4a3a910/ Asish Xavier is a Series C investor at Johnson & Johnson Development Corporation in Menlo Park focused on Biotechnology and Medical. Asish Xavier is the Vice President of Venture Investments at joined Johnson & Johnson Innovation - JJDC, Inc. (JJDC) in 2004. Asish is based in Silicon Valley, California. Asish previously worked in business development at BioRexis Pharmaceutical, Inc., which was acquired by Pfizer in 2007. While at BioRexis, Asish assisted the company inraising a $30 million second round of financing. Asish has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc. Asish received a Ph.D. from the University of Houston and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he graduated with honors. Asish received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. Asish was also a postdoctoral research Fellow in the Department of Chemistry at Johns Hopkins University. ## Investment focus ### Industry | Industry | Investments | Share | | --- | --- | --- | | Biotechnology | 8 | 57% | | Medical | 6 | 43% | | Health Care | 4 | 29% | | Therapeutics | 3 | 21% | | Biopharma | 2 | 14% | 10 industries tracked in total. ### Stage | Stage | Investments | Share | | --- | --- | --- | | Series C | 5 | 36% | | Series B | 4 | 29% | | Series A | 1 | 7% | | Funding Round | 1 | 7% | | Post-IPO Equity | 1 | 7% | ### Country | Country | Investments | Share | | --- | --- | --- | | United States | 6 | 43% | | Canada | 1 | 7% | | Australia | 1 | 7% | ## Investments | Company | Description | Amount | Stage | Date | Website | | --- | --- | --- | --- | --- | --- | | SonoThera | SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $125M | Series B | Jun 10, 2026 | | | SonoThera | SonoThera is a biotechnology company that creates non-viral genetic therapies using ultrasound. Its mission is to develop genetic medicines that treat the root cause of human disease. SonoThera is expanding the possibilities of disease treatment with ultrasound-guided nonviral gene therapy for diseases with suboptimal or non-existent treatments. Itaims to improve the lives and health of millions of people. | $60.8M | Series A | Dec 05, 2022 | | | PhaseBio Pharmaceuticals | PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity, and easeof administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects, and better patient compliance. Efficient production in E. coli ensures a low cost of goods.PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. Our second drug candidate, Vasomera, is currently being evaluated in phase 1 clinical trial and has exciting potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. Its third program, Insumera, basal insulin based on native human insulin, will enter clinical trials in early 2013.PhaseBio is based in Malvern, Pennsylvania. | $40M | Series C | Mar 12, 2015 | | | Protagonist Therapeutics | Protagonist Therapeutics is a biotechnology company dedicated to the discovery of novel peptide and small molecule compounds that mimic or inhibit therapeutically-relevant protein-protein interactions. | | Series B | Jun 04, 2013 | | | Aquinox Pharmaceuticals | Aquinox Pharmaceuticals Inc., a pharmaceutical company, engages in discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer and inflammatory disease. It offers AQX-MN100, a drug used to treat cancer and inflammatory disease, as well as SH2-containing inositol 5'-phosphatase inhibition program forblood cell recovery. The company was founded in 2004 and is based in Vancouver, Canada. | $18M | Series C | Apr 03, 2013 | | | Gyre Therapeutics | Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for thetreatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California. | | Post-IPO Equity | Apr 01, 2013 | | | Genocea Biosciences | Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalizedcancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines. | | Series C | Oct 10, 2012 | | | Gyre Therapeutics | Catalyst Biosciences is a drug discovery and development company. It is creating novel catalytic biopharmaceutical products based on engineered human proteases. The mission is to establish protease therapeutics as a new therapeutic platform comparable in depth and scope to antibody pharmaceuticals. The Company is developing proteases for thetreatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Founded in 1997, the company is headquartered in South San Francisco, California. | | Post-IPO Equity | Sep 25, 2012 | | | PhaseBio Pharmaceuticals | PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity, and easeof administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects, and better patient compliance. Efficient production in E. coli ensures a low cost of goods.PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. Our second drug candidate, Vasomera, is currently being evaluated in phase 1 clinical trial and has exciting potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. Its third program, Insumera, basal insulin based on native human insulin, will enter clinical trials in early 2013.PhaseBio is based in Malvern, Pennsylvania. | | Series B | Jun 05, 2012 | | | Genocea Biosciences | Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs.Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalizedcancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines. | $35M | Series B | Jan 03, 2011 | | 10 of 14 investments shown. ## Co-investors - [Asset Management Ventures (AMV)](https://shizune.co/investors/profile/asset-management-ventures) — VC Fund, 2 deals together - [Burrill & Company](https://shizune.co/investors/profile/burrill-co) — VC Fund, 2 deals together - [Cycad Group](https://shizune.co/investors/profile/cycad-group) — VC Fund, 2 deals together - [Essex Woodlands Healthcare Partners](https://shizune.co/investors/profile/essex-woodlands-health-ventures) — VC Fund, 2 deals together - [Fletcher Spaght, Inc.](https://shizune.co/investors/profile/fletcher-spaght-inc) — VC Fund, 2 deals together - [Hatteras Venture Partners](https://shizune.co/investors/profile/hatteras-venture-partners) — VC Fund, 2 deals together ## About Johnson & Johnson Development Corporation VC Fund · New Brunswick, United States Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms,JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.JJDC plays an integral role in the identification of new business opportunities outside of Johnson & Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies. 5 contacts available at Johnson & Johnson Development Corporation. | Name | Title | Profile | | --- | --- | --- | | Asish Xavier | Vice President, Venture Investments | https://shizune.co/investors/profile/asish-k-xavier | | Kadir Kadhiresan | Vice President, Venture Investments | https://shizune.co/investors/profile/v-kadir-kadhiresan | | James J. Bergin | Vice President Law | https://shizune.co/investors/profile/james-j-bergin | | Jeanne Bolger | Vice President Venture Investing | https://shizune.co/investors/profile/jeanne-bolger | | Marian Nakada | Vice President, Venture Investments | https://shizune.co/investors/profile/marian-nakada | ## Similar investors ### Similar stage - [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund - [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund - [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund ## FAQ ### What does Asish Xavier invest in? Asish Xavier invests primarily in Biotechnology, Medical and Health Care startups, most often at Series C and Series B stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio. ### When did Asish Xavier last invest? The most recent investment recorded for Asish Xavier closed in Jun 2026. Shizune tracks 14 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly. ### Is Shizune's investor data accurate? Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page. # About Shizune Shizune.co is an investor database. Core features: - 48,091 startup investors (angels, VCs, accelerators, and others) - Email, phone, LinkedIn (for intros), socials, and other contact data - Updated daily from public funding news - CSV and Excel export The User can access the full database FOR FREE after signing up: shizune.co